Trastuzumab deruxtecan shows durable activity in HER2-mutant non-small cell lung cancer

被引：0
|
作者：
O'Rourke, Kate
机构：
来源：
CANCER | 2022年 / 128卷 / 05期
关键词：
D O I：
10.1002/cncr.34102
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：938 / 938
页数：1
相关论文
共 50 条
  • [31] Trastuzumab in the treatment of non-small cell lung cancer
    Azzoli, CG
    Krug, LM
    Miller, VA
    Kris, MG
    Mass, R
    SEMINARS IN ONCOLOGY, 2002, 29 (01) : 59 - 65
  • [32] Trastuzumab deruxtecan in patients (pts) with HER2-overexpressing (HER2-OE) metastatic non-small cell lung cancer (NSCLC): Results from the DESTINY-Lung01 trial
    Smit, E. F.
    Felip, E.
    Uprety, D.
    Nakagawa, K.
    Paz-Ares, L.
    Pacheco, J.
    Li, B. T.
    Planchard, D.
    Baik, C.
    Goto, Y.
    Murakami, H.
    Saltos, A.
    Saxena, K.
    Shiga, R.
    Cheng, Y.
    Yan, Q.
    Feng, W.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S994 - S995
  • [33] A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer
    Hotta, Katsuyuki
    Aoe, Keisuke
    Kozuki, Toshiyuki
    Ohashi, Kadoaki
    Ninomiya, Kiichiro
    Ichihara, Eiki
    Kubo, Toshio
    Ninomiya, Takashi
    Chikamori, Kenichi
    Harada, Daijiro
    Nogami, Naoyuki
    Hirata, Taizo
    Hinotsu, Shiro
    Toyooka, Shinichi
    Kiura, Katsuyuki
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (02) : 273 - 279
  • [34] The efficacy of Ado-trastuzumab emtansine in HER-2 aberrant non-small cell lung cancer
    Xia, Yang
    Huang, Xiu
    Jin, Rui
    Li, Wen
    Shen, Huahao
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [35] FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations
    Mehta, Gautam U.
    Vellanki, Paz J.
    Ren, Yi
    Amatya, Anup K.
    Mishra-Kalyani, Pallavi S.
    Pan, Lili
    Zirkelbach, Jeanne F.
    Pan, Yuzhuo
    Liu, Jiang
    Aungst, Stephanie L.
    Miller, Claudia P.
    Shah, Mirat
    Rahman, Nam Atiqur
    Theoret, Marc
    Kluetz, Paul
    Pazdur, Richard
    Beaver, Julia A.
    Singh, Harpreet
    ONCOLOGIST, 2024, 29 (08): : 667 - 671
  • [36] A phase II study of [fam-] trastuzumab deruxtecan (DS-8201a) in HER2-overexpressing or -mutated advanced non-small cell lung cancer
    Planchard, D.
    Li, B. T.
    Murakami, H.
    Shiga, R.
    Lee, C. C.
    Wang, K.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [37] HER-2 Mutations in Non-Small Cell Lung Cancer
    Sen, Erdem
    Yavas, Guler
    Ata, Ozlem
    MEDICAL JOURNAL OF BAKIRKOY, 2018, 14 (03) : 322 - 325
  • [38] Prognostic and predictive implications of plasma ctDNA in guiding first-line targeted therapy for metastatic HER2-mutant non-small cell lung cancer (NSCLC)
    Liu, Si-Yang
    Jee, Justin
    Santini, Fernando Costa
    Schoenfeld, Adam Jacob
    Eichholz, Jordan
    Johnson, Kaylie
    Martinez, Andres
    Guo, Jiannan
    Riaz, Nadeem
    Lee, Nancy Y.
    Pike, Luke Roy George
    Scher, Howard I.
    Drilon, Alexander E.
    Arcila, Maria E.
    Reis-Filho, Jorge S.
    Razavi, Pedram
    Jones, David Randolph
    Rudin, Charles M.
    Isbell, James M.
    Li, Bob T.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [39] Trastuzumab Deruxtecan Shows Activity in Multiple HER2+ Tumors, Including Gynecologic Cancers
    Coleman
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (07) : 364 - 364
  • [40] Her2-targeted therapies in non-small cell lung cancer
    Swanton, Charles
    Futreal, Andy
    Eisen, Tim
    CLINICAL CANCER RESEARCH, 2006, 12 (14) : 4377S - 4383S
12345